However, only the immunopathological classification has been shown to significantly help clinicians in the therapeutic decision‐making process.3 The immunopathological classification of breast cancer is based on the expression of estrogen and progesterone receptors (ER/PR) and amplification of the human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast carcinoma.